Compare AMWD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWD | CGEM |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.8M | 794.7M |
| IPO Year | 1995 | 2020 |
| Metric | AMWD | CGEM |
|---|---|---|
| Price | $39.92 | $12.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $63.50 | $30.11 |
| AVG Volume (30 Days) | 227.3K | ★ 702.8K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,709,585,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $79.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.51 | $5.68 |
| 52 Week High | $72.16 | $16.74 |
| Indicator | AMWD | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 32.52 | 41.37 |
| Support Level | N/A | $11.43 |
| Resistance Level | $58.01 | $13.21 |
| Average True Range (ATR) | 1.76 | 0.86 |
| MACD | -0.05 | -0.37 |
| Stochastic Oscillator | 33.35 | 7.32 |
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.